In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ed Schoonveld

Advertisement
Set Alert for Articles By Ed Schoonveld

Latest From Ed Schoonveld

2017 Fair Pricing Forum: The Message For Pharma CEOs

Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.

BioPharmaceutical Market Access

The 21st Century Cures Act: Allowing The FDA To Address Modern Value Communication Needs

How to prove the real – and implicit – economic value of pharma products to payers and other stakeholders while FDA regulatory approvals adhere to a historically rigid standard of proof based on randomized tests against placebo in a controlled patient population? The 21st Century Cures Act may finally be extending a new path forward that offers legislative endorsement for use of a greater variety of evidence. What the FDA decides to do on this score is emerging as a key issue for biopharma in 2017.

BioPharmaceutical Market Access

Pharma Survival In A Transforming Global Payer Environment

Economic pressures and technological advances are forcing an unprecedented transformation of the payer environment. Biopharma companies must adjust their market access and pricing strategies to maintain competitively well-positioned and profitable organizations.

BioPharmaceutical Pricing Strategies
See All
Advertisement
UsernamePublicRestriction

Register